WO2005020972A3 - Polytherapie pour le traitement de troubles neovasculaires oculaires - Google Patents
Polytherapie pour le traitement de troubles neovasculaires oculaires Download PDFInfo
- Publication number
- WO2005020972A3 WO2005020972A3 PCT/US2004/027612 US2004027612W WO2005020972A3 WO 2005020972 A3 WO2005020972 A3 WO 2005020972A3 US 2004027612 W US2004027612 W US 2004027612W WO 2005020972 A3 WO2005020972 A3 WO 2005020972A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- combination therapy
- ocular neovascular
- neovascular disorders
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ546088A NZ546088A (en) | 2003-08-27 | 2004-08-26 | Combination therapy for the treatment of ocular neovascular disorders using a PDGF antagonist and a VEGF antagonist |
CN2004800317001A CN1934255B (zh) | 2003-08-27 | 2004-08-26 | 用于治疗眼新血管疾病的组合治疗 |
KR1020127022927A KR101471732B1 (ko) | 2003-08-27 | 2004-08-26 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
SI200431912T SI1660057T1 (sl) | 2003-08-27 | 2004-08-26 | Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti |
KR1020137034182A KR101501870B1 (ko) | 2003-08-27 | 2004-08-26 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
ES04782166T ES2388138T3 (es) | 2003-08-27 | 2004-08-26 | Terapia de combinación para tratamiento de trastornos neovasculares oculares |
AU2004268614A AU2004268614C1 (en) | 2003-08-27 | 2004-08-26 | Combination therapy for the treatment of ocular neovascular disorders |
PL04782166T PL1660057T3 (pl) | 2003-08-27 | 2004-08-26 | Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej |
DK04782166.5T DK1660057T3 (da) | 2003-08-27 | 2004-08-26 | Kombinationsterapi til behandling af neovaskulære øjenlidelser |
CA2536912A CA2536912C (fr) | 2003-08-27 | 2004-08-26 | Polytherapie pour le traitement de troubles neovasculaires oculaires |
EP04782166A EP1660057B1 (fr) | 2003-08-27 | 2004-08-26 | Polytherapie pour le traitement de troubles neovasculaires oculaires |
KR1020067004047A KR101218889B1 (ko) | 2003-08-27 | 2004-08-26 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
JP2006524824A JP4951339B2 (ja) | 2003-08-27 | 2004-08-26 | 眼血管新生疾患の治療のための併用療法 |
BRPI0413977-1A BRPI0413977A (pt) | 2003-08-27 | 2004-08-26 | método para suprimir um distúrbio neovascular, e para tratar um paciente diagnosticado com ou em risco de desenvolver um distúrbio neovascular, composição farmacêutica, e, embalagem farmacêutica |
HK06112988.3A HK1092367A1 (en) | 2003-08-27 | 2006-11-27 | Combination therapy for the treatment of ocular neovascular disorders |
AU2010224423A AU2010224423B2 (en) | 2003-08-27 | 2010-09-24 | Combination therapy for the treatment of ocular neovascular disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49840703P | 2003-08-27 | 2003-08-27 | |
US60/498,407 | 2003-08-27 | ||
US55683704P | 2004-03-26 | 2004-03-26 | |
US60/556,837 | 2004-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005020972A2 WO2005020972A2 (fr) | 2005-03-10 |
WO2005020972A3 true WO2005020972A3 (fr) | 2005-11-17 |
Family
ID=34278595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/027612 WO2005020972A2 (fr) | 2003-08-27 | 2004-08-26 | Polytherapie pour le traitement de troubles neovasculaires oculaires |
Country Status (19)
Country | Link |
---|---|
US (9) | US7759472B2 (fr) |
EP (3) | EP3168304A1 (fr) |
JP (4) | JP4951339B2 (fr) |
KR (3) | KR101471732B1 (fr) |
CN (3) | CN102380098B (fr) |
AR (1) | AR046682A1 (fr) |
AU (2) | AU2004268614C1 (fr) |
BR (1) | BRPI0413977A (fr) |
CA (3) | CA2903196A1 (fr) |
CY (1) | CY1113058T1 (fr) |
DK (1) | DK1660057T3 (fr) |
ES (1) | ES2388138T3 (fr) |
HK (1) | HK1092367A1 (fr) |
NZ (4) | NZ592039A (fr) |
PL (1) | PL1660057T3 (fr) |
PT (1) | PT1660057E (fr) |
SI (1) | SI1660057T1 (fr) |
TW (3) | TWI484965B (fr) |
WO (1) | WO2005020972A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8946184B2 (en) | 2005-02-14 | 2015-02-03 | Archemix Llc | Aptamer therapeutics useful in the treatment of complement-related disorders |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120183593A1 (en) * | 2003-04-09 | 2012-07-19 | Directcontact Llc | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
EP1620547B1 (fr) * | 2003-04-21 | 2014-06-18 | Archemix LLC | Aptameres stabilises lies a un facteur de croissance derive de plaquette et leur utilisation en tant qu'agents therapeutiques d'oncologie |
BRPI0413977A (pt) | 2003-08-27 | 2006-11-07 | Osi Eyetech Inc | método para suprimir um distúrbio neovascular, e para tratar um paciente diagnosticado com ou em risco de desenvolver um distúrbio neovascular, composição farmacêutica, e, embalagem farmacêutica |
ATE551060T1 (de) * | 2004-06-04 | 2012-04-15 | Scripps Research Inst | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen |
EP2319492A3 (fr) * | 2004-10-21 | 2011-08-10 | Genentech, Inc. | Procédé pour le traitement de maladies néovasculaires intraoculaires |
US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
CN101141975B (zh) | 2005-03-25 | 2012-05-23 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for the diagnosis of preeclampsia |
AU2006300234B2 (en) * | 2005-10-14 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
CN101330930B (zh) * | 2005-10-21 | 2011-11-23 | 中外制药株式会社 | 心脏病治疗剂 |
AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
TW200803894A (en) * | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
CA2633063A1 (fr) * | 2005-12-16 | 2007-06-21 | Diatos | Conjugues peptidiques de penetration cellulaire pour la delivrance d'acides nucleiques dans une cellule |
AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
US8673873B1 (en) * | 2005-12-28 | 2014-03-18 | Alcon Research, Ltd. | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders |
US8771686B2 (en) * | 2006-01-27 | 2014-07-08 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody |
JP2009525282A (ja) * | 2006-01-30 | 2009-07-09 | (オーエスアイ)アイテツク・インコーポレーテツド | 血管新生疾患の治療のための組み合わせ療法 |
AU2013204622B2 (en) * | 2006-03-08 | 2016-04-21 | Archemix Llc | Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders |
HUE026496T2 (en) * | 2006-03-08 | 2016-06-28 | Archemix Llc | Complement-binding aptamers and anti-C5 agents for treating eye diseases |
WO2007116962A1 (fr) * | 2006-04-07 | 2007-10-18 | Osaka University | Promoteur de régénération musculaire |
US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 vegf 길항제 제형 |
US20080081791A1 (en) * | 2006-07-06 | 2008-04-03 | Weida Huang | Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi |
US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
MX2009007830A (es) * | 2007-01-23 | 2009-10-07 | Univ Shinshu | Inhibidor de rechazo cronico. |
WO2008103320A1 (fr) * | 2007-02-16 | 2008-08-28 | Novacea, Inc. | Méthodes de traitement de troubles ophtalmiques utilisant des anthraquinones |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US20080286338A1 (en) * | 2007-05-15 | 2008-11-20 | Boston Foundation For Sight | Drug delivery system with scleral lens |
JP5425180B2 (ja) * | 2008-03-27 | 2014-02-26 | ザイモジェネティクス, インコーポレイテッド | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
TWI528973B (zh) * | 2008-06-05 | 2016-04-11 | Chugai Pharmaceutical Co Ltd | Nerve infiltration inhibitor |
WO2010097800A1 (fr) * | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Combinaison synergique de composés bioactifs pour diminuer la pression intraoculaire |
WO2010127029A1 (fr) * | 2009-05-01 | 2010-11-04 | Ophthotech Corporation | Procédés de traitement ou de prévention de maladies ophtalmologiques |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
US9539322B2 (en) | 2010-05-28 | 2017-01-10 | National University Corporation Hokkaido University | Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody |
EP2418279A1 (fr) * | 2010-08-10 | 2012-02-15 | Gene Signal International SA | Composition pharmaceutique injectable pour prévenir, stabiliser et/ou inhiber des états liés à une néovascularisation pathologique |
US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
US9682144B2 (en) | 2011-06-30 | 2017-06-20 | Gene Signal International, Sa | Composition comprising inhibitors of IRS-1 and of VEGF |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
WO2013040079A1 (fr) | 2011-09-13 | 2013-03-21 | Dose Medical Corporation | Capteur physiologique intra-oculaire |
CA3098762C (fr) | 2012-03-26 | 2023-01-17 | Glaukos Corporation | Systeme et procede de pose d'implants oculaires multiples |
JP6587934B2 (ja) | 2012-03-28 | 2019-10-09 | ソマロジック・インコーポレーテッド | Pdgfおよびvegf結合アプタマー、および、pdgfおよびvegfが介在する病気の治療へのそれらの使用 |
EA201492289A1 (ru) * | 2012-06-01 | 2015-05-29 | Офтотек Корпорейшн | Композиции, содержащие аптамер против pdgf и антагонист vegf |
KR101386697B1 (ko) * | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
AU2013283296A1 (en) | 2012-06-28 | 2015-02-05 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
TWI663985B (zh) | 2012-09-27 | 2019-07-01 | 美商歐樂根公司 | 用於持續釋放蛋白質之可生物降解的藥物傳遞系統 |
SG11201501914XA (en) | 2012-10-11 | 2015-05-28 | Ascendis Pharma Ophthalmology Division As | Vegf neutralizing prodrugs for the treatment of ocular conditions |
IL239682B (en) | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
RU2712621C2 (ru) | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
CN103254286A (zh) * | 2013-05-30 | 2013-08-21 | 苏州普罗达生物科技有限公司 | 一种vegfr2酪氨酸激酶抑制剂多肽及其应用 |
AU2014288847A1 (en) * | 2013-07-11 | 2016-01-28 | Novartis Ag | Use of a VEGF antagonist in treating retinopathy of prematurity |
EP3628373A1 (fr) | 2013-07-12 | 2020-04-01 | IVERIC bio, Inc. | Procédés de traitement ou de prévention des affections ophtalmologiques |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
CN105683179B (zh) | 2013-08-14 | 2018-10-26 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶的抑制剂 |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
SI3041513T1 (sl) | 2013-09-08 | 2020-11-30 | Kodiak Sciences Inc. | Zwitterionski polimerni konjugati faktorja VIII |
US9695424B2 (en) * | 2013-09-09 | 2017-07-04 | Somalogic, Inc. | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders |
AU2014348667A1 (en) | 2013-11-15 | 2016-06-02 | Glaukos Corporation | Ocular implants configured to store and release stable drug formulations |
JP6655610B2 (ja) | 2014-05-29 | 2020-02-26 | グローコス コーポレーション | 制御された薬物送達機能を備えるインプラント及びそれを使用する方法 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3170005B1 (fr) | 2014-07-18 | 2019-04-10 | Sanofi | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
WO2016022914A1 (fr) * | 2014-08-08 | 2016-02-11 | Moderna Therapeutics, Inc. | Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
JP6946184B2 (ja) * | 2014-11-10 | 2021-10-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗pdgf−b抗体及び使用法 |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
KR101721059B1 (ko) * | 2014-12-26 | 2017-03-30 | 주식회사 아이바이오코리아 | 안구 표면 질환 예방 또는 치료용 약학조성물 |
US20180289253A1 (en) * | 2015-05-22 | 2018-10-11 | Indiana University Research & Technology Corporation | Methods and systems for patient specific identification and assessmentof ocular disease risk factors and treatment efficacy |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
ES2819030T3 (es) * | 2016-04-08 | 2021-04-14 | Eyebio Korea | Péptido basado en colágeno tipo II alfa-1 útil para el tratamiento de una enfermedad de la superficie ocular |
EP3442479A1 (fr) | 2016-04-20 | 2019-02-20 | Harold Alexander Heitzmann | Dispositif d'administration de médicament oculaire biorésorbable |
KR20220107319A (ko) | 2016-05-31 | 2022-08-02 | 칼비스타 파마슈티컬즈 리미티드 | 혈장 칼리크레인 저해제로서 피라졸 유도체 |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
RU2669787C2 (ru) * | 2016-12-13 | 2018-10-16 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Средство для лечения заболевания, сопровождающегося отеком макулы вследствие повышенной экспрессии VEGF-A |
KR20190121816A (ko) | 2017-04-03 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
SG11201909154SA (en) | 2017-04-05 | 2019-10-30 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
EP3620531A4 (fr) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles |
CA3076833A1 (fr) | 2017-09-29 | 2019-04-04 | Glaukos Corporation | Capteur physiologique intraoculaire |
JP2020536967A (ja) | 2017-10-12 | 2020-12-17 | イミュノウェイク インコーポレイテッド | Vegfr−抗体軽鎖融合タンパク質 |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
HRP20220367T1 (hr) | 2017-11-29 | 2022-05-27 | Kalvista Pharmaceuticals Limited | Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor |
WO2019210097A1 (fr) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamères ayant une stabilité, une puissance ou une demi-vie pour une sécurité et une efficacité améliorées |
EP4364724A2 (fr) | 2018-05-10 | 2024-05-08 | Regeneron Pharmaceuticals, Inc. | Formulations contenant une protéine de fusion à haute concentration du récepteur vegf |
EP4010333A1 (fr) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
WO2021032935A1 (fr) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzyme |
WO2021032933A1 (fr) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzymes |
CA3147566A1 (fr) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzyme |
WO2021032936A1 (fr) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzymes |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
EP4126940A1 (fr) | 2020-03-30 | 2023-02-08 | F. Hoffmann-La Roche AG | Anticorps se liant à vegf et pdgf-b et méthodes d'utilisation |
WO2021247901A1 (fr) * | 2020-06-05 | 2021-12-09 | Occurx Pty. Ltd. | Composés et procédés de traitement de troubles oculaires |
KR20230128413A (ko) | 2020-12-01 | 2023-09-04 | 칼비스타 파마슈티컬즈 리미티드 | 효소 저해제 |
CN114366712B (zh) * | 2022-01-25 | 2023-10-24 | 上海交通大学医学院附属第九人民医院 | 用于治疗脉络膜新生血管的药物凝胶混合物 |
WO2024038282A1 (fr) | 2022-08-18 | 2024-02-22 | Kalvista Pharmaceuticals Limited | Dérivés de 2-aza- et 2-oxabicyclo[2.1.1]hexane utilisés comme inhibiteurs de l'enzyme du facteur xiia |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995016032A1 (fr) * | 1993-12-09 | 1995-06-15 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Acide nucleique antisens pour le traitement de maladies dans lesquelles l'expression de bfgf, pdgf-a ou pdgf-b joue un role pathogene |
WO1996027006A2 (fr) * | 1995-03-02 | 1996-09-06 | Hybridon, Inc. | Oligonucleotides antisens specifiques du facteur de croissance de l'endothelium vasculaire humain |
US6051698A (en) * | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
WO2001027264A1 (fr) * | 1999-10-15 | 2001-04-19 | Nihon University, School Juridical Person | Ribozymes agissant sur un facteur de croissance provenant des plaquettes humaines |
WO2001087351A1 (fr) * | 2000-05-17 | 2001-11-22 | Gilead Sciences, Inc. | Methode de traitement des tumeurs au moyen de ligands d'acide nucleique reactifs vis-a-vis de pdgf |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US976534A (en) | 1909-09-15 | 1910-11-22 | August Wolff | Window. |
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
FR2594438B1 (fr) | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
US5322691A (en) | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
ATE113059T1 (de) | 1987-06-24 | 1994-11-15 | Florey Howard Inst | Nukleosid-derivate. |
IL87181A (en) | 1987-08-07 | 1993-08-18 | Sanofi Sa | Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them |
US4914210A (en) * | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US6005087A (en) * | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US6147204A (en) | 1990-06-11 | 2000-11-14 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
US5668264A (en) | 1990-06-11 | 1997-09-16 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5674685A (en) | 1990-06-11 | 1997-10-07 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
US5811533A (en) | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5496938A (en) * | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US6465188B1 (en) * | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
ATE154246T1 (de) | 1990-07-27 | 1997-06-15 | Isis Pharmaceuticals Inc | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
AU648630B2 (en) | 1990-12-21 | 1994-04-28 | Creative Biomolecules, Inc. | Biosynthetic PDGF antagonists |
AU1411092A (en) | 1991-01-31 | 1992-09-07 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2102780C (fr) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Composes de type bis-monoaryle, aryle bicyclique et (ou) heteroaryle inhibant l'activite de tyrosine kinase des recepteurs de l'egf et (ou) du pdgf |
US6762290B1 (en) | 1999-07-29 | 2004-07-13 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
WO1993006213A1 (fr) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production d'anticorps chimeriques - une approche combinatoire |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
ATE226093T1 (de) | 1991-11-26 | 2002-11-15 | Isis Pharmaceuticals Inc | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (fr) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
US5869462A (en) | 1992-09-10 | 1999-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
US5821234A (en) | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5620687A (en) | 1993-02-25 | 1997-04-15 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors |
US5976534A (en) | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
US6410322B1 (en) * | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US6306829B1 (en) | 1995-12-08 | 2001-10-23 | Hybridon, Inc. | Modified VEGF oligonucleotides for treatment of skin disorders |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5952304A (en) | 1993-10-22 | 1999-09-14 | Trigen Limited | Platelet-derived growth factor analogues |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
US5840301A (en) | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
US6448077B1 (en) | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5958942A (en) | 1994-07-15 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Tricyclic nitrogen ring compounds, their production and use |
CA2156767A1 (fr) | 1994-08-25 | 1996-02-26 | Kenichi Matsunaga | Agent liant pour facteur de croissance |
US5476851A (en) | 1994-09-08 | 1995-12-19 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase |
US5795910A (en) | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
US6403088B1 (en) | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5723750A (en) | 1995-01-12 | 1998-03-03 | Vanderbilt University | Transgenic plants expressing disassembly deficient viral coat proteins |
US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
US5611135A (en) | 1995-03-21 | 1997-03-18 | Dana Corporation | Method of making a tube yoke for drive line assembly |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5859228A (en) | 1995-05-04 | 1999-01-12 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
US5723594A (en) | 1995-06-07 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
DE69636656T2 (de) | 1995-06-02 | 2007-10-04 | Gilead Sciences, Inc., Foster City | Oligonukleotidliganden mit hoher affinität für pdgf |
US6229002B1 (en) * | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
US6699843B2 (en) * | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
US5618837A (en) | 1995-06-07 | 1997-04-08 | Zymogenetics, Inc. | PDGF antagonists III |
AU5938696A (en) | 1995-06-30 | 1997-02-05 | Zymogenetics Inc. | 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists |
US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
DE69628652T3 (de) | 1995-09-08 | 2012-05-03 | Genentech, Inc. | Vegf-verwandtes protein |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
WO1997032856A1 (fr) | 1996-03-05 | 1997-09-12 | Zeneca Limited | Derives de 4-anilinoquinazoline |
WO1997034876A1 (fr) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Derives de cinnoline et leur emploi comme medicaments |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
JP2002504086A (ja) | 1996-05-01 | 2002-02-05 | イーライ・リリー・アンド・カンパニー | Vegf関連疾患の治療的処置 |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
FR2752734B1 (fr) | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
JP2001501471A (ja) | 1996-09-24 | 2001-02-06 | メルク エンド カンパニー インコーポレーテッド | 血管新生の阻害のための遺伝子治療 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
AU719392B2 (en) | 1996-10-01 | 2000-05-11 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compounds |
US6426335B1 (en) | 1997-10-17 | 2002-07-30 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
JP3837748B2 (ja) | 1997-01-17 | 2006-10-25 | 東亞合成株式会社 | Vegf結合性ポリペプチド |
US6291667B1 (en) | 1997-01-31 | 2001-09-18 | Parkash S. Gill | Method and composition for treatment of kaposi's sarcoma |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
PT1325932E (pt) | 1997-04-07 | 2005-06-30 | Genentech Inc | Anticorpos anti-vegf |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6278039B1 (en) | 1997-05-28 | 2001-08-21 | Axys Pharmaceuticals, Inc. | C. elegans deletion mutants |
US5932580A (en) | 1997-12-01 | 1999-08-03 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds their preparation and compositions |
US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
WO2000023565A2 (fr) | 1998-10-19 | 2000-04-27 | Ludwig Institute For Cancer Research | Nouvelle liaison neuropiline/facteur de croissance et applications de celle-ci |
WO2000025805A1 (fr) | 1998-11-02 | 2000-05-11 | Ludwig Institute For Cancer Research | Proteine du facteur de croissance endothelial vasculaire (vegf) isolee de la souche nz2 du virus orf se liant au recepteur du vegf de mammifere et l'activant |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
DK1140175T3 (da) | 1998-12-21 | 2006-08-14 | Ludwig Inst Cancer Res | Antistoffer mod trunkeret VEGF-D og anvendelser deraf |
US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
WO2000060115A2 (fr) | 1999-04-02 | 2000-10-12 | City Of Hope | Methode d'identification de sites de liaison accessibles dans l'arn |
JP4926320B2 (ja) | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
US6382219B1 (en) * | 1999-06-08 | 2002-05-07 | Jeffery A. Jelten | Tooth flossing device |
US7303746B2 (en) * | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
PT1221917E (pt) | 1999-10-21 | 2005-04-29 | Alcon Inc | Dispositivo para ministrar medicamentos |
US6358954B1 (en) | 1999-11-09 | 2002-03-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
WO2001072829A2 (fr) | 2000-03-31 | 2001-10-04 | Institut Pasteur | Peptides inhibant l'angiogenese induite par le vegf (facteur de croissance endotheliale), polynucleotides codant pour ces peptides et leurs procedes d'utilisation |
AU7141701A (en) | 2000-08-30 | 2002-03-13 | Univ Johns Hopkins | Devices for intraocular drug delivery |
WO2003070910A2 (fr) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Inhibition induite par interference d'arn du facteur de croissance endothelial vasculaire et expression genetique du recepteur de facteur de croissance endothelial vasculaire au moyen d'acides nucleiques interferents courts (sina) |
WO2004003211A1 (fr) | 2002-06-26 | 2004-01-08 | Imclone Systems Incorporated | Anticorps bispecifiques qui se lient aux recepteurs de vegf |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
FR2828601B1 (fr) | 2001-08-10 | 2003-11-07 | Iroc Technologies | Ensemble de circuits electroniques comportant des moyens de decontamination de parties contaminees par des erreurs |
WO2003020276A1 (fr) * | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Inhibiteurs de tyrosine kinase |
EP1436329A4 (fr) | 2001-09-20 | 2005-04-27 | Alexion Pharma Inc | Anticorps anti-pdgf et procedes de production d'anticorps mis au point |
IL161327A0 (en) | 2001-11-09 | 2004-09-27 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
CA2487809A1 (fr) | 2002-06-18 | 2003-12-24 | Archemix Corp. | Molecules toxine-aptamere et procedes d'utilisation correspondants |
US20040249130A1 (en) | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
US20070184089A1 (en) | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
TWI283406B (en) * | 2002-08-28 | 2007-07-01 | Brilliance Semiconductor Inc | Charging-free ultra-low power virtual dynamic random access memory |
US8003117B2 (en) * | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
JP4412461B2 (ja) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
US8828373B2 (en) * | 2002-11-20 | 2014-09-09 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
US20050124565A1 (en) | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US20090053138A1 (en) | 2002-11-21 | 2009-02-26 | Preiss Jeffrey R | Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics |
AU2003294437A1 (en) | 2002-11-21 | 2004-06-18 | Archemix Corporation | Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same |
US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US20040253243A1 (en) * | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US20060257381A1 (en) * | 2003-06-27 | 2006-11-16 | Keiya Ozawa | Method for transplanting lymphohematopoietic cells into mammal |
BRPI0413977A (pt) | 2003-08-27 | 2006-11-07 | Osi Eyetech Inc | método para suprimir um distúrbio neovascular, e para tratar um paciente diagnosticado com ou em risco de desenvolver um distúrbio neovascular, composição farmacêutica, e, embalagem farmacêutica |
US20050063257A1 (en) * | 2003-09-24 | 2005-03-24 | Clark David G. | Audio bookmark |
US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
US20050244471A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
US8529927B2 (en) | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US20050244500A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
US20050244462A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
JP2008537538A (ja) | 2005-02-11 | 2008-09-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Vegf拮抗剤及び降圧剤の治療的組み合わせ |
JP2009540011A (ja) | 2006-06-12 | 2009-11-19 | エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. | 血管新生のsiRNA阻害のための組成物及び方法 |
KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 vegf 길항제 제형 |
EP2091481A2 (fr) | 2006-12-18 | 2009-08-26 | Alcon Research, Ltd. | Dispositifs et procédés pour l'administration de médicaments ophtalmiques |
WO2008134077A1 (fr) | 2007-04-30 | 2008-11-06 | Archemix Corp. | Pharmacie chimique utilisant des aptamères dirigés contre un profil métabolique |
WO2008153997A1 (fr) | 2007-06-07 | 2008-12-18 | Brookwood Pharmaceuticals, Inc. | Formes de dosage à action prolongée et à masse réduite |
WO2010127029A1 (fr) | 2009-05-01 | 2010-11-04 | Ophthotech Corporation | Procédés de traitement ou de prévention de maladies ophtalmologiques |
CN102122763A (zh) * | 2011-03-17 | 2011-07-13 | 东南大学 | 并联馈电的全向阵列天线 |
-
2004
- 2004-08-26 BR BRPI0413977-1A patent/BRPI0413977A/pt not_active IP Right Cessation
- 2004-08-26 CN CN201110271111.2A patent/CN102380098B/zh not_active Expired - Fee Related
- 2004-08-26 NZ NZ592039A patent/NZ592039A/xx not_active IP Right Cessation
- 2004-08-26 WO PCT/US2004/027612 patent/WO2005020972A2/fr active Application Filing
- 2004-08-26 EP EP16002068.1A patent/EP3168304A1/fr not_active Withdrawn
- 2004-08-26 NZ NZ546088A patent/NZ546088A/en not_active IP Right Cessation
- 2004-08-26 PT PT04782166T patent/PT1660057E/pt unknown
- 2004-08-26 ES ES04782166T patent/ES2388138T3/es active Active
- 2004-08-26 NZ NZ61708304A patent/NZ617083A/en not_active IP Right Cessation
- 2004-08-26 SI SI200431912T patent/SI1660057T1/sl unknown
- 2004-08-26 CA CA2903196A patent/CA2903196A1/fr not_active Abandoned
- 2004-08-26 DK DK04782166.5T patent/DK1660057T3/da active
- 2004-08-26 CN CN201210165474.2A patent/CN102813923B/zh not_active Expired - Fee Related
- 2004-08-26 EP EP04782166A patent/EP1660057B1/fr active Active
- 2004-08-26 KR KR1020127022927A patent/KR101471732B1/ko not_active IP Right Cessation
- 2004-08-26 CA CA2876822A patent/CA2876822C/fr not_active Expired - Fee Related
- 2004-08-26 KR KR1020137034182A patent/KR101501870B1/ko not_active IP Right Cessation
- 2004-08-26 CA CA2536912A patent/CA2536912C/fr not_active Expired - Fee Related
- 2004-08-26 NZ NZ601544A patent/NZ601544A/xx not_active IP Right Cessation
- 2004-08-26 AU AU2004268614A patent/AU2004268614C1/en not_active Ceased
- 2004-08-26 EP EP20100013061 patent/EP2281885A1/fr not_active Withdrawn
- 2004-08-26 PL PL04782166T patent/PL1660057T3/pl unknown
- 2004-08-26 KR KR1020067004047A patent/KR101218889B1/ko not_active IP Right Cessation
- 2004-08-26 US US10/926,806 patent/US7759472B2/en not_active Expired - Fee Related
- 2004-08-26 JP JP2006524824A patent/JP4951339B2/ja not_active Expired - Fee Related
- 2004-08-26 CN CN2004800317001A patent/CN1934255B/zh not_active Expired - Fee Related
- 2004-08-27 TW TW103128503A patent/TWI484965B/zh not_active IP Right Cessation
- 2004-08-27 TW TW102122763A patent/TWI484964B/zh not_active IP Right Cessation
- 2004-08-27 AR ARP040103086A patent/AR046682A1/es unknown
- 2004-08-27 TW TW093125925A patent/TWI414300B/zh not_active IP Right Cessation
-
2006
- 2006-11-27 HK HK06112988.3A patent/HK1092367A1/xx not_active IP Right Cessation
-
2009
- 2009-05-13 US US12/465,051 patent/US8206707B2/en not_active Expired - Fee Related
- 2009-09-22 US US12/564,863 patent/US8187597B2/en not_active Expired - Fee Related
- 2009-12-17 US US12/641,270 patent/US8685397B2/en not_active Expired - Fee Related
-
2010
- 2010-09-24 AU AU2010224423A patent/AU2010224423B2/en not_active Ceased
-
2011
- 2011-01-10 US US12/987,508 patent/US20110200593A1/en not_active Abandoned
- 2011-10-28 JP JP2011236920A patent/JP2012072152A/ja active Pending
-
2012
- 2012-08-02 CY CY20121100687T patent/CY1113058T1/el unknown
-
2014
- 2014-02-21 US US14/186,149 patent/US20140242082A1/en not_active Abandoned
- 2014-06-13 US US14/303,973 patent/US20140294816A1/en not_active Abandoned
- 2014-07-18 JP JP2014147781A patent/JP2014237674A/ja not_active Withdrawn
-
2015
- 2015-01-16 US US14/598,365 patent/US20150202288A1/en not_active Abandoned
- 2015-01-30 US US14/610,332 patent/US20150202289A1/en not_active Abandoned
-
2016
- 2016-07-07 JP JP2016134790A patent/JP2017014215A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995016032A1 (fr) * | 1993-12-09 | 1995-06-15 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Acide nucleique antisens pour le traitement de maladies dans lesquelles l'expression de bfgf, pdgf-a ou pdgf-b joue un role pathogene |
WO1996027006A2 (fr) * | 1995-03-02 | 1996-09-06 | Hybridon, Inc. | Oligonucleotides antisens specifiques du facteur de croissance de l'endothelium vasculaire humain |
US6051698A (en) * | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
WO2001027264A1 (fr) * | 1999-10-15 | 2001-04-19 | Nihon University, School Juridical Person | Ribozymes agissant sur un facteur de croissance provenant des plaquettes humaines |
WO2001087351A1 (fr) * | 2000-05-17 | 2001-11-22 | Gilead Sciences, Inc. | Methode de traitement des tumeurs au moyen de ligands d'acide nucleique reactifs vis-a-vis de pdgf |
Non-Patent Citations (6)
Title |
---|
BERGERS GABRIELE ET AL: "Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.", JOURNAL OF CLINICAL INVESTIGATION, vol. 111, no. 9, May 2003 (2003-05-01), pages 1287 - 1295, XP002317731, ISSN: 0021-9738 * |
DATABASE WPI Section Ch Week 200129, Derwent World Patents Index; Class B04, AN 2001-282025, XP002317734 * |
GREEN L S ET AL: "NUCLEASE-RESISTANT NUCLEIC ACID LIGANDS TO VASCULAR PERMEABILITY FACTOR/VASCULAR ENDOTHELIAL GROWTH FACTOR", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 10, no. 2, October 1995 (1995-10-01), pages 683 - 695, XP001084803, ISSN: 1074-5521 * |
KE LIDAO ET AL: "A novel approach to glioma gene therapy: Down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 12, no. 6, June 1998 (1998-06-01), pages 1391 - 1396, XP008043063, ISSN: 1019-6439 * |
ZHANG LIN ET AL: "Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 303, no. 4, 18 April 2003 (2003-04-18), pages 1169 - 1178, XP002317732, ISSN: 0006-291X * |
ZHANG WEI ET AL: "A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model.", ANGIOGENESIS, vol. 5, no. 1-2, 2002, pages 35 - 44, XP002342903, ISSN: 0969-6970 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8946184B2 (en) | 2005-02-14 | 2015-02-03 | Archemix Llc | Aptamer therapeutics useful in the treatment of complement-related disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005020972A3 (fr) | Polytherapie pour le traitement de troubles neovasculaires oculaires | |
WO2005027839A3 (fr) | Procedes et reactifs pour le traitement des troubles immuno-inflammatoires | |
WO2007087457A3 (fr) | Polytherapie destinee au traitement de troubles neovasculaires | |
WO2004073614A3 (fr) | Polytherapie servant au traitement de troubles immuno-inflammatoires | |
WO2005037203A3 (fr) | Procedes et reactifs pour le traitement de troubles inflammatoires | |
WO2005079284A3 (fr) | Methodes et reactifs pour le traitement de maladies et de troubles lies a des niveaux accrus de cytokines proinflammatoires | |
WO2007056457A3 (fr) | Procedes, compositions et kits pour le traitement de pathologies | |
WO2007103373A3 (fr) | Compositions et procédés pour le traitement de troubles immunoinflammatoires | |
WO2005066337A3 (fr) | Composes, compositions pharmaceutiques et procedes therapeutiques pour prevenir et traiter des maladies et des troubles associes a la formation de fibrilles amyloides | |
WO2006036770A3 (fr) | Therapie combinatoire dans le traitement de l'obesite | |
WO2006002437A3 (fr) | Traitement d'etats pathologiques impliquant la demyelinisation | |
DK1608350T3 (da) | Fremgangsm der til forebyggelse, behandling og diagnosticering af lidelser af proteinaggregation | |
WO2004071431A3 (fr) | Composition et methode de traitement de troubles neurodegeneratifs | |
WO2004019863A3 (fr) | Therapie de combinaison pour le traitement de troubles fibrosants | |
EP1478371A4 (fr) | Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline | |
BR0308290A (pt) | Tratamento e prevenção de distúrbios inflamatórios | |
WO2006074265A3 (fr) | Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires | |
WO2006138372A3 (fr) | Procedes et reactifs pour le traitement de troubles inflammatoires | |
WO2004110380A3 (fr) | Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques | |
WO2003092617A3 (fr) | Combinaisons destinees au traitement de troubles cutanes inflammatoires | |
WO2007123848A3 (fr) | Préparations thérapeutiques contenant des protéines slrp de classe i modifiées | |
WO2005092062A3 (fr) | Composes destines aux troubles neurodegeneratifs | |
WO2005051293A3 (fr) | Procedes et reactifs destines au traitement de troubles inflammatoires | |
WO2008016640A3 (fr) | Traitement de l'insuffisance cardiaque progressive chronique | |
WO2005048927A3 (fr) | Procedes et reactifs pour le traitement de troubles inflammatoires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480031700.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2536912 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004782166 Country of ref document: EP Ref document number: 2006524824 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067004047 Country of ref document: KR Ref document number: PA/a/2006/002293 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004268614 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 546088 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2004268614 Country of ref document: AU Date of ref document: 20040826 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004268614 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004782166 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0413977 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067004047 Country of ref document: KR |